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In Japan, the entrance air kerma rate (EAKR) to a patient cannot exceed 50 mGy/min in 
conventional fluoroscopy. However, it’s unclear where the EAKR should be measured. 
We obtained the tube potential and tube current as a function of polymethylmethacrylate 
(PMMA) thickness, and the EAKR at the interventional reference point (IRP) was 
measured from the trajectory. The EAKR at the point established by the U.S. Food and 
Drug Administration (FDA) was calculated from EAKR at the IRP. The EAKR at the 
IRP exceeded the limit at a PMMA thickness of 22–28 cm. However, the EAKR did not 
exceed the limit at the FDA point. If the EAKR to a patient is being verified to meet the 
recent Japanese ruling, the EAKR should be measured at the FDA point, and if the 
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A ruling enacted by the Japanese Ministry of Health, Labour, and Welfare in 2001 [1] 
states that the entrance air kerma rate (EAKR) to a patient must not exceed 50 mGy/min 
in conventional fluoroscopy, and 125 mGy/min in special fluoroscopy in a 
high-dose-rate mode. Compliance with medical regulations is mandatory for clinical 
physicists and those in related fields, but it is still unclear where the EAKR to the 
patient should be measured.  
International Electrotechnical Commission (IEC) standard 60601-2-43 defines an 
interventional reference point (IRP) as a location that is representative of the patient’s 
skin [2]. For typical isocentric interventional equipment, the default IRP is located on 
the central axis of the X-ray beam at 15 cm on the X-ray tube side of the isocenter.  
The U.S. Food and Drug Administration (FDA) defines the C-arm measurement point 
as 30 cm in front of the image receptor (FDA point) for any source-to-image receptor 
distance (SID). Fluoroscopic equipment with an SID tracking system must maintain the 
88 mGy/min limit at the FDA point at any SID [3]. 
We introduced new surgical fluoroscopic equipment in December 2011, and its 
automatic exposure control (AEC) system was verified on acceptance testing. 
Subsequently, we found that the EAKR at the IRP exceeded 50 mGy/min. To our 
3 
 
knowledge, this is the first report to focus on the location where the EAKR to a patient 
should be measured to meet Japanese regulations. 
 
 
2. Methods and materials 
As part of the acceptance testing of an Opescope Pleno WHA-200 surgical fluoroscopy 
system (Shimadzu Corporation, Kyoto, Japan), verification of its AEC system was 
performed under a fixed geometric arrangement. The system provided two modes: 
“normal,” a conventional fluoroscopy mode, and “high quality,” a high-dose-rate 
fluoroscopy mode. Three types of aluminum filters were installed in the system. The 
experimental setup of this fixed geometry is depicted in Fig. 1, and the technical 
specifications of this system are listed in Table 1. A lateral X-ray tube position was 
applied in all measurements.  
First, we plotted the tube potential (kVp) and tube current (mA) as a function of the 
nominal polymethylmethacrylate (PMMA) thickness when an additional copper filter (0, 
0.1, and 0.2 mm) was changed, as shown in Fig. 1(A) (trajectory acquisitions). A 0.3 
mm copper filter was not applied in the acceptance testing because we do not use the 
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filter in a clinical setting. We employed PMMA plastic phantom to simulate patient 
thicknesses varying from 0 to 28 cm. 
Second, we measured the EAKR (mGy/min) at the IRP as shown in Fig. 1(B). We 
used an Unfors Xi semiconductor detector (Unfors RaySafe, Billdal, Sweden) was used 
to measure the EAKR without backscatter. The dosimeter has 1 mm of lead behind the 
detector as protection from backscattered photons. Because using a dosimeter in tandem 
with AEC leads to unpredictable and undesirable levels of EAKR, AEC was not applied, 
and the tube potential and tube current were set manually by use of the initially obtained 
trajectory as a function of PMMA thickness. The EAKR at the FDA point was 
calculated with these geometrical factors: SID, 90 cm; source-isocenter distance, 55 cm; 
source-dosimeter (IRP) distance, 40 cm; and source-FDA point distance, 60 cm.  
Upon completion of all data acquisition, the tube potential, tube current, average 
power (W), and EAKR at both the IRP and the FDA point were plotted against the 
PMMA thickness.  
 
3. Results 
Figure 2 shows the fluoroscopic tube potential, tube current, average power (W), and 
EAKR at the IRP / FDA point and as a function of the PMMA thickness in normal 
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mode without a spectral filter (0 mm Cu). Chart A of Figure. 2 shows the fluoroscopic 
tube potential and tube current, chart B shows average power loading, and chart C 
shows the EAKR at the IRP / FDA point. The tube potential and tube current show a 
monotonic increase as the phantom thickness is increased up to the thickness that 
produces the maximum average power load for the system. The maximum tube 
potential and tube current were 110 kVp and 3.0 mA for the normal mode. The EAKR 
was also increased with the maximum average power load. The limit for the EAKR at 
the IRP exceeded 50 mGy/min in the normal mode when a PMMA thickness of 22–28 
cm was applied without spectral filter (0 mm copper). However, the limit for the EAKR 




The Japan Association on Radiological Protection in Medicine and many others have 
reported that the EAKR with backscatter must be measured at the IRP by use of PMMA 
[4]. On the other hand, the IEC, FDA, and Japanese medical regulatory authorities agree 
that the kerma rates are intended to mean EAKR without backscatter (free in air). 
Therefore, we applied the EAKR without backscatter to verify the 50 mGy/min limit.  
6 
 
The EAKR at the IRP exceeded the limit of 50 mGy/min when a PMMA thickness of 
22–28 cm was applied without a spectral filter (0 mm copper). If the EAKR to a patient 
is verified at the IRP during acceptance testing, the dose might be overestimated. 
However, the regulation does not define the measurement point. Then, where should 
“EAKR to patient” be measured during acceptance testing? The manufacturer must be 
able to comply with the Japanese regulations to be permitted to sell a system. 
 Although the Japan Association on Radiological Protection in Medicine and others 
have proposed that the EAKR be measured at the IRP, the manufacturer applies the 
FDA point when evaluating the EAKR to a patient (in free air) [5]. Our data show that, 
on our system, the EAKR at the FDA point was within the limit (50 mGy/min). 
Acceptance testing of the AEC with other spectral filters (1-mm Cu, 2-mm Cu) in 
normal mode and AEC in the high-dose-rate mode also was performed at initial 
installation. The limits of 50 mGy/min or 125 mGy/min at IRP / FDA point were not 
exceeded in all circumstances.  
The Unfors Xi semiconductor detector is designed for application in conventional 
radiography and fluoroscopy dosimetry measurement. As such, the lead support was 
embedded in the detector to shield any backscatter from being detected. It might be 
important to consider the backscatter from the lead when the EAKR is measured. 
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However, the detector was duly calibrated with an error of 1.5% in the manufacture’s 
factory. 
We have found that (1) when the EAKR to a patient is verified to meet the regulation, 
the dose must be measured and evaluated at the FDA point, (2) if the EAKR is being 
evaluated for determining the skin dose in a clinical setting, the dose must be monitored 
at the IRP, because many investigations and useful conversion factors have been based 




If the EAKR to a patient is being verified to meet the recent Japanese ruling, the dose 
should be measured and evaluated at the FDA point, and if the EAKR is being 
evaluated for determination of the skin dose in a clinical setting, the dose should be 
monitored at the IRP. 
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Experimental setup. The trajectory of the tube potential and tube current was obtained in 
setting (A) as a function of PMMA thickness. Entrance air kerma rates measured in 
setting (B) are in accordance with the trajectory obtained. 
 
Fig. 2 
Fluoroscopic tube potential, tube current, entrance air kerma at the IRP / FDA point, 
and average power as a function of the PMMA thickness in “normal” mode without 
spectral filter (0 mm). When 22-cm-thick PMMA was applied to simulate a patient, the 
EAKR at the IRP exceeded the limit of the Japanese regulation. The EAKR at the FDA 
point was not exceeded in all circumstances. 
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Table 1. Technical information on Shimadzu Opescope Pleno WHA-200 surgical fluoroscopic system 
1. X-ray tube 
   1.1 Focal spot size                                                            0.6 mm  
   1.2 Target angle                                                                8 ° 
2. X-ray tube assembly           
   2.1 Total filtration                                                             2.9 mm Al equivalent 
   2.2 Spectral filters                                                              0.1 mm Cu, 0.2 mm Cu, 0.3 mm Cu 
3. C-arm / geometry 
   3.1 Source-image receptor distance                                  90.0 cm 
   3.2 Source-isocenter distance                                            55.0 cm 
   3.3 Source-IRP* distance                                                   40.0 cm 
   3.4 Source-FDA* point distance                                        60.0 cm 
   3.5 Field of view                                                                23.0 cm / 16.0 cm (diamter) 
4. Fluoroscopic mode 
   4.1 Pulse rate                                                                   0.5, 1, 2, 3.75, 7.5, 15, 30 (continuous) * 
   4.3 Tube potential                                                               40-110 kVp                   
   4.3 Maximum tube current                                                 9.0 mA 
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Fig 2(C) 
Chart C 
